Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

Pantoprazole does not reduce upper gastrointestinal bleeding during anticoagulation treatment

07 Aug 2019

Proton pump inhibitor therapy, particularly with pantoprazole, does not reduce upper gastrointestinal bleeding events in patients taking low-dose anticoagulation/aspirin treatment, reports a recent study.

Researchers randomly assigned 17,598 patients with stable cardiovascular and peripheral artery disease to receive either daily 40-mg pantoprazole (n=8,791; mean age, 67.6±8.1 years; 22 percent female) or placebo (n=8,807; mean age, 67.7±8.1 years; 21 percent female). Participants were also given rivaroxaban 2.5 mg twice daily with 100-mg aspirin once daily, rivaroxaban 5 mg twice daily or aspirin 100 mg alone.

The primary efficacy outcome of clinically significant events in the upper gastrointestinal tract occurred in 1.2 percent (n=102) of the pantoprazole arm and in 1.3 percent (n=116) of the placebo group. The difference did not reach significance (hazard ratio [HR], 0.88, 95 percent CI, 0.67–1.15).

Further analysis according to the components of upper gastrointestinal bleeding showed that both treatment arms were comparable in terms of overt or occult bleeding events. However, the likelihood of gastroduodenal bleeding was significantly attenuated in patients who were given pantoprazole (HR, 0.52, 0.28–0.94; p=0.03).

In a subsequent posthoc analysis where the definition of bleeding events was broadened, pantoprazole use remained significantly associated with a lower risk of bleeding of gastroduodenal lesions (HR, 0.45, 0.27–0.74). Pantoprazole also exerted a significant protective effect against peptic ulcer (HR, 0.46, 0.25–0.83) and erosions (HR, 0.13–0.84).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.